drugset / Trial / NCT06861179

The Formulation of Compound Phellinus Igniarius Decoction on Radiation Pneumonitis

NCT06861179 ↗

Phase 1 Completed 40 enrolled Zhejiang Cancer Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this clinical trial were to determine the radioprotective effects and underlying biological mechanisms of Phellinus igniarius and its active components during radiotherapy in patients with thoracic malignant tumors. The study group was given the formulation of Compound Phellinus igniarius decoction daily during radiotherapy, 150ml bid until the end of radiotherapy; The control group only received standard dose radiotherapy without the formulation of Compound Phellinus igniarius decoction intervention. The baseline differences between the two groups were compared, including gender, smoking history, body mass index (BMI), pathological classification, median age of onset, inflammatory factors, tumor markers, TNM stage, KPS score, fatigue score, incidence and grade of radiation pneumonitis, incidence of other radiotherapy-related adverse reactions, and average radiation dose.

Timeline

Start
2023-03-22
Primary completion
2024-12-28
Completion
2024-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Compound Phellinus igniarius decoction Traditional medicine (herbal / TCM) 150 ml —

Indications